FDA Calendar Updates: FDA Panel Rejects King’s Imaging Agent |
![]() |
![]() |
Tuesday, 28 July 2009 16:29 |
On 7/28/09, an FDA Advisory Panel voted that King's experimental heart imaging agent, CorVue, failed to demonstrate equivalent imaging results as an older, approved agent (adenosine). In an 11-5 vote, the FDA Advisory Panel stated that the Company's study results failed to establish a high degree of similarity between images generated by CorVue and adenosine. The final FDA decision for the pending CorVue NDA is expected to occur during early 4Q09. Disclosure: No positions "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |